Last reviewed · How we verify
Eupaverin (MOXAVERINE)
Eupaverin (generic name: MOXAVERINE) is a moxaverine drug. It is currently in Phase 2 development.
Eupaverin works by interacting with specific biological pathways to produce its effects.
Eupaverin is a small molecule with the synonyms MOXAVERINA, MOXAVERINE, MOXAVERINE, and MOXAVERINE. It has been studied in clinical trials for conditions such as macular degeneration, glaucoma, and ischemia, with interventions including moxaverine and placebo.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MOXAVERINE |
|---|---|
| Drug class | moxaverine |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's physiological processes as a complex orchestra. Eupaverin is like a conductor that helps the different instruments work together in harmony. By modulating these processes, it can help restore balance and alleviate symptoms.
Approved indications
Common side effects
Key clinical trials
- A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects (PHASE2)
- An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects (PHASE2,PHASE3)
- Effects of Moxaverine and Placebo on Ocular Blood Flow (PHASE2)
- A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eupaverin CI brief — competitive landscape report
- Eupaverin updates RSS · CI watch RSS
Frequently asked questions about Eupaverin
What is Eupaverin?
How does Eupaverin work?
What is the generic name of Eupaverin?
What drug class is Eupaverin in?
What development phase is Eupaverin in?
Related
- Drug class: All moxaverine drugs
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing